Molecular Partners AG (MOLN.SW)

CHF 3.16

(-3.66%)

Total Assets Summary of Molecular Partners AG

Molecular Partners AG's latest annual total assets in 2023 was 198.35 Million CHF , down -24.37% from previous year.
Molecular Partners AG's latest quarterly total assets in 2024 Q3 was 154.21 Million CHF , down -9.62% from previous quarter.
Molecular Partners AG reported annual total assets of 262.25 Million CHF in 2022, up 51.89% from previous year.
Molecular Partners AG reported annual total assets of 172.66 Million CHF in 2021, down -7.93% from previous year.
Molecular Partners AG reported quarterly total assets of 154.21 Million CHF for 2024 Q3, down -9.62% from previous quarter.
Molecular Partners AG reported quarterly total assets of 185.6 Million CHF for 2024 Q1, down -6.43% from previous quarter.

Annual Total Assets Chart of Molecular Partners AG (2023 - 2013)

Historical Annual Total Assets of Molecular Partners AG (2023 - 2013)

Year	Total Assets	Total Assets Growth
2023	198.35 Million CHF	-24.37%
2022	262.25 Million CHF	51.89%
2021	172.66 Million CHF	-7.93%
2020	187.54 Million CHF	78.73%
2019	104.93 Million CHF	-32.37%
2018	155.15 Million CHF	7.43%
2017	144.42 Million CHF	-21.55%
2016	184.09 Million CHF	-16.09%
2015	219.39 Million CHF	13.08%
2014	194.01 Million CHF	76.2%
2013	110.11 Million CHF	0.0%

Year	Total Assets	Total Assets Growth
2024 Q2	170.61 Million CHF	-8.08%
2024 Q3	154.21 Million CHF	-9.62%
2024 Q1	185.6 Million CHF	-6.43%
2023 Q3	218.11 Million CHF	-5.37%
2023 FY	198.35 Million CHF	-24.37%
2023 Q1	244.53 Million CHF	-6.76%
2023 Q4	198.35 Million CHF	-9.06%
2023 Q2	230.49 Million CHF	-5.74%
2022 Q2	299.29 Million CHF	-4.02%
2022 Q4	262.25 Million CHF	-6.72%
2022 Q1	311.84 Million CHF	80.6%
2022 Q3	281.16 Million CHF	-6.06%
2022 FY	262.25 Million CHF	51.89%
2021 FY	172.66 Million CHF	-7.93%
2021 Q2	206.98 Million CHF	19.62%
2021 Q4	172.66 Million CHF	-2.1%
2021 Q3	176.36 Million CHF	-14.79%
2021 Q1	173.03 Million CHF	-7.74%
2020 Q2	73.33 Million CHF	0.0%
2020 Q4	187.54 Million CHF	0.0%
2020 Q1	- CHF	-100.0%
2020 FY	187.54 Million CHF	78.73%
2019 Q4	104.93 Million CHF	0.0%
2019 FY	104.93 Million CHF	-32.37%
2019 Q1	134.88 Million CHF	-13.07%
2019 Q2	134.88 Million CHF	0.0%
2019 Q3	104.93 Million CHF	-22.2%
2018 Q1	127.43 Million CHF	-11.76%
2018 Q2	127.43 Million CHF	0.0%
2018 Q4	155.15 Million CHF	0.0%
2018 Q3	155.15 Million CHF	21.75%
2018 FY	155.15 Million CHF	7.43%
2017 FY	144.42 Million CHF	-21.55%
2017 Q4	144.42 Million CHF	0.0%
2017 Q3	144.42 Million CHF	-10.32%
2017 Q2	161.04 Million CHF	0.0%
2017 Q1	- CHF	-100.0%
2016 FY	184.09 Million CHF	-16.09%
2016 Q3	- CHF	-100.0%
2016 Q1	- CHF	-100.0%
2016 Q4	184.09 Million CHF	0.0%
2016 Q2	200.61 Million CHF	0.0%
2015 Q4	219.39 Million CHF	0.0%
2015 Q2	193.5 Million CHF	0.0%
2015 Q1	- CHF	-100.0%
2015 FY	219.39 Million CHF	13.08%
2014 FY	194.01 Million CHF	76.2%
2014 Q4	194.01 Million CHF	0.0%
2014 Q1	- CHF	0.0%
2013 FY	110.11 Million CHF	0.0%

Peer Total Assets Comparison of Molecular Partners AG

Name	Total Assets	Total Assets Difference
Addex Therapeutics Ltd	4.64 Million CHF	-4173.872%
BB Biotech AG	2.63 Billion CHF	92.479%
Basilea Pharmaceutica AG	173.28 Million CHF	-14.463%
Evolva Holding SA	9.82 Million CHF	-1918.193%
Idorsia Ltd	499.99 Million CHF	60.329%
Kuros Biosciences AG	75.9 Million CHF	-161.313%
Relief Therapeutics Holding AG	76.39 Million CHF	-159.657%
Santhera Pharmaceuticals Holding AG	109.62 Million CHF	-80.93%